Lv11
60 积分 2025-02-27 加入
Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective
17天前
已完结
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
17天前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer The GEMSTONE-303 Randomized Clinical Trial
21天前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer The GEMSTONE-303 Randomized Clinical Trial
21天前
已完结
Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective
28天前
已完结
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
28天前
已完结
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
28天前
已完结
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective
1个月前
已完结
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
2个月前
已完结
皖公网安备34019202002308
